CIK 0001870404
- Emerging growth company
CERO THERAPEUTICS HOLDINGS, INC.
Sign in to watch- Tickers
- CERO CEROW
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 871088814
- Phone
- +1 650-407-2376
- Business address
- 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CERO THERAPEUTICS HOLDINGS, INC., PHOENIX BIOTECH ACQUISITION CORP.
Securities
- CERO Common stock OTC
- CEROW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-07 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +690,900 | 690,900 | ||
| 2025-05-30 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +9,326 | 9,326 | ||
| 2025-03-04 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +17,923 | 17,923 | ||
| 2025-02-24 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +127,500 | 255,000 | ||
| 2024-12-02 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +127,500 | 127,500 | ||
| 2024-09-25 | LAPORTE KATHLEEN Director | Exercise or conversion | +965,997 | 965,997 | ||
| 2024-09-25 | LAPORTE KATHLEEN Director | Exercise or conversion · Series A Convertible Preferred Stock | −50 | $1,000.00 | $50K | 0 |
| 2024-03-25 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2024-02-14 | LAPORTE KATHLEEN Director | Grant or award · Series A Convertible Preferred Stock | +50 | $1,000.00 | $50K | 50 |
| 2024-02-14 | LAPORTE KATHLEEN Director | Other acquisition | +5,828 | 5,828 | ||
| 2024-02-14 | LAPORTE KATHLEEN Director | Grant or award · Series A Convertible Preferred Stock | +50 | $1,000.00 | $50K | 50 |
| 2021-10-08 | LAPORTE KATHLEEN Director | Other acquisition · Class B Common Stock | +17,500 | 17,500 |
Page 1 of 1 · 12 trades